Kazia Therapeuticsの価格/販売
Kazia Therapeuticsの価格/販売は何ですか。
Kazia Therapeutics Limitedの価格/販売は1.93です。
価格/販売の定義は何ですか。
価格対売上比率は、収益と比較した会社の株価です。
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
ASXのセクタHealth Careにおける価格/販売の企業と比べるKazia Therapeutics
Kazia Therapeuticsは何をしますか。
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Kazia Therapeuticsと類似の価格/販売
- Grand T G Goldの価格/販売は1.92です。
- C4X Discovery Plcの価格/販売は1.93です。
- China ITS () Coの価格/販売は1.93です。
- Kandi Technologiesの価格/販売は1.93です。
- Obsidianの価格/販売は1.93です。
- Whiting Petroleum Dl ,001の価格/販売は1.93です。
- Kazia Therapeuticsの価格/販売は1.93です。
- The Indian Card Clothingの価格/販売は1.93です。
- Qingdao Port International Coの価格/販売は1.93です。
- Anheuser-Busch InBev SA/NVの価格/販売は1.93です。
- Kiri Industriesの価格/販売は1.93です。
- EyePoint Pharmaceuticals Incの価格/販売は1.93です。
- Cerebra Integrated Technologiesの価格/販売は1.93です。